Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients

NCT02301910 is registered in ClinicalTrials.gov with Supergene, LLC as lead sponsor.

NCT NCT02301910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02301910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients
Lead sponsor
Supergene, LLC
Phase
Phase 3
Overall status
Completed
Start date
May 16, 2014
Completion date
December 1, 2016
Enrollment
382 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction